Table 1 Baseline patients’ characteristics in the whole case series and according to the presence or absence of TE events.
From: Risk assessment of thromboembolic events in hospitalized cancer patients
Characteristic | Total (N = 535) | Without TE (N = 506) | With TE (N = 29) | p value |
|---|---|---|---|---|
Age, median (IQR) | 64 (56–72) | 64 (56–72) | 69 (61–73) | 0.292 |
Gender, male | 277 (51.8) | 257 (50.8) | 20 (69.0) | 0.087 |
BMI, median (IQR) | 24 (21–26) | 24 (21–26) | 23 (22–25) | 0.761 |
≥ 35 kg/m2 | 7 (1.3) | 7 (1.4) | – | |
ECOG PS | 0.081 | |||
0–1 | 442 (82.6) | 422 (83.4) | 20 (69.0) | |
≥ 2 | 93 (17.4) | 84 (16.6) | 9 (31.0) | |
Smoking status | 0.070 | |||
Never | 333 (66.5) | 316 (66.9) | 17 (58.6) | |
Former | 110 (22.0) | 99 (21.0) | 11 (38.0) | |
Current | 58 (11.6) | 57 (12.1) | 1 (3.4) | |
NA | 34 | 34 | – | |
Cancer type | 0.909 | |||
CUP | 9 (1.7) | 8 (1.6) | 1 (3.4) | |
Lung | 122 (22.8) | 114 (22.5) | 8 (27.6) | |
Breast | 44 (8.2) | 43 (8.5) | 1 (3.4) | |
Colorectal | 105 (19.6) | 100 (19.8) | 5 (17.2) | |
Pancreatic | 37 (6.9) | 35 (6.9) | 2 (6.9) | |
Gastric and GEJ | 75 (14.0) | 72 (14.2) | 3 (10.3) | |
Biliary Tract | 29 (5.4) | 27 (5.3) | 2 (6.9) | |
Oesophageal | 15 (2.8) | 14 (2.8) | 1 (3.4) | |
Renal | 8 (1.5) | 8 (1.6) | – | |
Melanoma | 10 (1.9) | 10 (2.0) | – | |
Anal | 23 (4.3) | 22 (4.3) | 1 (3.4) | |
Prostate | 8 (1.5) | 7 (1.4) | 1 (3.4) | |
Bladder | 3 (0.6) | 3 (0.6) | – | |
Other | 47 (8.8) | 43 (8.5) | 4 (13.8) | |
Stage | 0.325 | |||
Locally advanced | 123 (23.0) | 119 (23.5) | 4 (13.8) | |
Metastatic | 412 (77.0) | 387 (76.5) | 25 (86.2) | |
Number of metastatic sites | 0.248 | |||
≤ 2 | 374 (69.9) | 357 (70.6) | 17 (58.6) | |
> 2 | 161 (30.1) | 149 (29.4) | 12 (41.4) | |
Ongoing anticancer treatment platinum-based CT | 0.453 | |||
No | 277 (51.8) | 264 (52.2) | 13 (44.8) | |
Yes | 258 (48.2) | 242 (47.8) | 16 (55.2) | |
Gemcitabine-based CT | 0.479 | |||
No | 494 (92.3) | 468 (92.5) | 26 (89.7) | |
Yes | 41 (7.7) | 38 (7.5) | 3 (10.3) | |
Targeted therapy | 0.103 | |||
No | 458 (85.6) | 430 (85.0) | 28 (96.6) | |
Yes | 77 (14.4) | 76 (15.0) | 1 (3.4) | |
Immune checkpoint inhibitors | 0.425 | |||
No | 498 (93.3) | 473 (93.5) | 25 (89.3) | |
Yes | 36 (6.7) | 33 (6.5) | 3 (10.7) | |
NA | 1 | – | 1 | |
Endocrine therapy | 0.282 | |||
No | 514 (96.3) | 488 (96.4) | 26 (92.9) | |
Yes | 20 (3.7) | 18 (3.6) | 2 (7.1) | |
NA | 1 | – | 1 | |
Anti-angiogenic therapy | 1.000 | |||
No | 514 (96.3) | 487 (96.2) | 27 (96.4) | |
Yes | 20 (3.7) | 19 (3.8) | 1 (3.6) | |
NA | 1 | – | 1 | |
Reason for hospitalization | 0.016 | |||
Acute respiratory insufficiency | 5 (0.9) | 5 (1.0) | – | |
Biopsy | 83 (15.5) | 79 (15.6) | 4 (13.8) | |
Cancer progression/CT toxicity | 23 (4.3) | 23 (4.5) | – | |
CVC placement | 19 (3.6) | 17 (3.4) | 2 (6.9) | |
Diarrhea | 4 (0.7) | 2 (0.4) | 2 (6.9) | |
Dysphagia | 2 (0.4) | 1 (0.2) | 1 (3.4) | |
Fever/acute infection | 33 (6.2) | 30 (5.9) | 3 (10.3) | |
Intestinal (sub-)occlusion | 6 (1.1) | 6 (1.2) | – | |
Immune related adverse events | 4 (0.7) | 4 (0.8) | – | |
Malnutrition/cachexia | 10 (1.9) | 8 (1.6) | 2 (6.9) | |
Nausea-vomiting | 3 (0.6) | 3 (0.6) | – | |
Obstructive jaundice | 2 (0.4) | 2 (0.4) | – | |
Other | 13 (2.4) | 11 (2.2) | 2 (6.9) | |
Pleural effusion | 15 (2.8) | 15 (3.0) | - | |
Refractory pain | 11 (2.1) | 10 (2.0) | 1 (3.4) | |
Treatment Administration | 302 (56.4) | 290 (57.3) | 12 (41.4) | |
LOS, days, median (IQR) | 5 (3–8) | 5 (3–8) | 6 (5–14) | 0.032 |
Fever during hospitalization | 56 (10.5) | 51 (10.1) | 5 (17.2) | 0.361 |
Use of antiplatelet agents | 63 (11.8) | 59 (11.7) | 4 (13.8) | 0.960 |
Use of LWMH | 56 (10.5) | 53 (10.5) | 3 (10.3) | 1.000 |
Khorana score | 0.960 | |||
0 | 153 (28.6) | 146 (28.9) | 7 (24.1) | |
1 | 154 (28.8) | 146 (28.9) | 9 (31.0) | |
2 | 140 (26.2) | 131 (25.8) | 8 (27.6) | |
≥ 3 | 88 (16.4) | 83 (16.4) | 5 (17.2) | |
Vascular compression | 63 (12.1) | 51 (10.3) | 12 (44.4) | < .001 |
NA | 13 | 11 | 2 | |
Previous TEs | 29 (5.4) | 25 (5.0) | 4 (14.3) | 0.058 |
NA | 2 | 1 | 1 | |
